Preservation of cell-based immunotherapies for clinical trials

R. U.I. LI, RACHEL JOHNSON, GUANGLIN YU, David H McKenna, Allison Hubel

Research output: Contribution to journalReview article

Abstract

In the unique supply chain of cellular therapies, preservation is important to keep the cell product viable. Many factors in cryopreservation affect the outcome of a cell therapy: (i) formulation and introduction of a freezing medium, (ii) cooling rate, (iii) storage conditions, (iv) thawing conditions and (v) post-thaw processing. This article surveys clinical trials of cellular immunotherapy that used cryopreserved regulatory, chimeric antigen receptor or gamma delta T cells, dendritic cells or natural killer (NK) cells. Several observations are summarized from the given information. The aforementioned cell types have been similarly frozen in media containing 5–10% dimethyl sulfoxide (DMSO) with plasma, serum or human serum albumin. Two common freezing methods are an insulated freezing container such as Nalgene Mr. Frosty and a controlled-rate freezer at a cooling rate of -1°C/min. Water baths at approximately 37°C have been commonly used for thawing. Post-thaw processing of cryopreserved cells varied greatly: some studies infused the cells immediately upon thawing; some diluted the cells in a carrier solution of varying formulation before infusion; some washed cells to remove cryoprotective agents; and others re-cultured cells to recover cell viability or functionality lost due to cryopreservation. Emerging approaches to preserving cellular immunotherapies are also described. DMSO-free formulations of the freezing media have demonstrated improved preservation of cell viability in T lymphocytes and of cytotoxic function in natural killer cells. Saccharides are a common type of molecule used as an alternative cryoprotective agent to DMSO. Improving methods of preservation will be critical to growth in the clinical use of cellular immunotherapies.

Original languageEnglish (US)
Pages (from-to)943-957
Number of pages15
JournalCytotherapy
Volume21
Issue number9
DOIs
StatePublished - Sep 1 2019

Fingerprint

Immunotherapy
Clinical Trials
Freezing
Dimethyl Sulfoxide
Cryoprotective Agents
Cryopreservation
Natural Killer Cells
Cell Survival
Antigen Receptors, T-Cell, gamma-delta
Cytotoxic T-Lymphocytes
Cell- and Tissue-Based Therapy
Baths
Serum Albumin
Dendritic Cells
Cultured Cells
Water
Growth
Serum

Keywords

  • T cells
  • cell therapies
  • cryopreservation
  • dendritic cells
  • natural killer cells

Cite this

Preservation of cell-based immunotherapies for clinical trials. / LI, R. U.I.; JOHNSON, RACHEL; YU, GUANGLIN; McKenna, David H; Hubel, Allison.

In: Cytotherapy, Vol. 21, No. 9, 01.09.2019, p. 943-957.

Research output: Contribution to journalReview article

LI, R. U.I. ; JOHNSON, RACHEL ; YU, GUANGLIN ; McKenna, David H ; Hubel, Allison. / Preservation of cell-based immunotherapies for clinical trials. In: Cytotherapy. 2019 ; Vol. 21, No. 9. pp. 943-957.
@article{98cf6cc99f25468497f35fa86fcd73eb,
title = "Preservation of cell-based immunotherapies for clinical trials",
abstract = "In the unique supply chain of cellular therapies, preservation is important to keep the cell product viable. Many factors in cryopreservation affect the outcome of a cell therapy: (i) formulation and introduction of a freezing medium, (ii) cooling rate, (iii) storage conditions, (iv) thawing conditions and (v) post-thaw processing. This article surveys clinical trials of cellular immunotherapy that used cryopreserved regulatory, chimeric antigen receptor or gamma delta T cells, dendritic cells or natural killer (NK) cells. Several observations are summarized from the given information. The aforementioned cell types have been similarly frozen in media containing 5–10{\%} dimethyl sulfoxide (DMSO) with plasma, serum or human serum albumin. Two common freezing methods are an insulated freezing container such as Nalgene Mr. Frosty and a controlled-rate freezer at a cooling rate of -1°C/min. Water baths at approximately 37°C have been commonly used for thawing. Post-thaw processing of cryopreserved cells varied greatly: some studies infused the cells immediately upon thawing; some diluted the cells in a carrier solution of varying formulation before infusion; some washed cells to remove cryoprotective agents; and others re-cultured cells to recover cell viability or functionality lost due to cryopreservation. Emerging approaches to preserving cellular immunotherapies are also described. DMSO-free formulations of the freezing media have demonstrated improved preservation of cell viability in T lymphocytes and of cytotoxic function in natural killer cells. Saccharides are a common type of molecule used as an alternative cryoprotective agent to DMSO. Improving methods of preservation will be critical to growth in the clinical use of cellular immunotherapies.",
keywords = "T cells, cell therapies, cryopreservation, dendritic cells, natural killer cells",
author = "LI, {R. U.I.} and RACHEL JOHNSON and GUANGLIN YU and McKenna, {David H} and Allison Hubel",
year = "2019",
month = "9",
day = "1",
doi = "10.1016/j.jcyt.2019.07.004",
language = "English (US)",
volume = "21",
pages = "943--957",
journal = "Cytotherapy",
issn = "1465-3249",
publisher = "Informa Healthcare",
number = "9",

}

TY - JOUR

T1 - Preservation of cell-based immunotherapies for clinical trials

AU - LI, R. U.I.

AU - JOHNSON, RACHEL

AU - YU, GUANGLIN

AU - McKenna, David H

AU - Hubel, Allison

PY - 2019/9/1

Y1 - 2019/9/1

N2 - In the unique supply chain of cellular therapies, preservation is important to keep the cell product viable. Many factors in cryopreservation affect the outcome of a cell therapy: (i) formulation and introduction of a freezing medium, (ii) cooling rate, (iii) storage conditions, (iv) thawing conditions and (v) post-thaw processing. This article surveys clinical trials of cellular immunotherapy that used cryopreserved regulatory, chimeric antigen receptor or gamma delta T cells, dendritic cells or natural killer (NK) cells. Several observations are summarized from the given information. The aforementioned cell types have been similarly frozen in media containing 5–10% dimethyl sulfoxide (DMSO) with plasma, serum or human serum albumin. Two common freezing methods are an insulated freezing container such as Nalgene Mr. Frosty and a controlled-rate freezer at a cooling rate of -1°C/min. Water baths at approximately 37°C have been commonly used for thawing. Post-thaw processing of cryopreserved cells varied greatly: some studies infused the cells immediately upon thawing; some diluted the cells in a carrier solution of varying formulation before infusion; some washed cells to remove cryoprotective agents; and others re-cultured cells to recover cell viability or functionality lost due to cryopreservation. Emerging approaches to preserving cellular immunotherapies are also described. DMSO-free formulations of the freezing media have demonstrated improved preservation of cell viability in T lymphocytes and of cytotoxic function in natural killer cells. Saccharides are a common type of molecule used as an alternative cryoprotective agent to DMSO. Improving methods of preservation will be critical to growth in the clinical use of cellular immunotherapies.

AB - In the unique supply chain of cellular therapies, preservation is important to keep the cell product viable. Many factors in cryopreservation affect the outcome of a cell therapy: (i) formulation and introduction of a freezing medium, (ii) cooling rate, (iii) storage conditions, (iv) thawing conditions and (v) post-thaw processing. This article surveys clinical trials of cellular immunotherapy that used cryopreserved regulatory, chimeric antigen receptor or gamma delta T cells, dendritic cells or natural killer (NK) cells. Several observations are summarized from the given information. The aforementioned cell types have been similarly frozen in media containing 5–10% dimethyl sulfoxide (DMSO) with plasma, serum or human serum albumin. Two common freezing methods are an insulated freezing container such as Nalgene Mr. Frosty and a controlled-rate freezer at a cooling rate of -1°C/min. Water baths at approximately 37°C have been commonly used for thawing. Post-thaw processing of cryopreserved cells varied greatly: some studies infused the cells immediately upon thawing; some diluted the cells in a carrier solution of varying formulation before infusion; some washed cells to remove cryoprotective agents; and others re-cultured cells to recover cell viability or functionality lost due to cryopreservation. Emerging approaches to preserving cellular immunotherapies are also described. DMSO-free formulations of the freezing media have demonstrated improved preservation of cell viability in T lymphocytes and of cytotoxic function in natural killer cells. Saccharides are a common type of molecule used as an alternative cryoprotective agent to DMSO. Improving methods of preservation will be critical to growth in the clinical use of cellular immunotherapies.

KW - T cells

KW - cell therapies

KW - cryopreservation

KW - dendritic cells

KW - natural killer cells

UR - http://www.scopus.com/inward/record.url?scp=85070414536&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070414536&partnerID=8YFLogxK

U2 - 10.1016/j.jcyt.2019.07.004

DO - 10.1016/j.jcyt.2019.07.004

M3 - Review article

VL - 21

SP - 943

EP - 957

JO - Cytotherapy

JF - Cytotherapy

SN - 1465-3249

IS - 9

ER -